An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.
Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.
Survivors of pediatric cancer have a higher rate of clonal hematopoiesis than their peers at any age, a study suggests.
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
Medication errors may be common in children with leukemia or lymphoma, and these errors can lead to serious harm, a new study suggests.
Hodgkin lymphoma patients treated with subdiaphragmatic radiation and/or procarbazine have an increased risk of developing colorectal cancer, a study suggests.
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Researchers observed improvements in overall survival and progression-free survival with peripheral blood vs bone marrow transplants.
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
The CARMEN regimen appears effective in patients with MYC-rearranged aggressive lymphoma, including those who are HIV-positive.
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
Crizotinib plus chemotherapy appears effective for pediatric patients with newly diagnosed ALCL, but the combination increases the risk of thrombosis.
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
The FDA has approved Lunsumio (mosunetuzumab-axgb) to treat adults with relapsed/refractory follicular lymphoma after 2 or more lines of systemic therapy.
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.